Clinical application of dendritic cells in cancer vaccination therapy

APMIS

Volumn 111, Issue 7-8, 2003, Pages 818-834

  Svane, Inge Marie ^a   Soot, Mette Line ^a   Buus, Søren ^b   Johnsen, Hans E ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer vaccine; Clinical trial; Dendritic cell; T cell

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD40 ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CD86 ANTIGEN; CELL ANTIGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; GLYCOPROTEIN GP 100; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; MUCIN 1; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PAIN; CELL CULTURE; CELL FUNCTION; CELL POPULATION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EVALUATION; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; LABORATORY TEST; METHODOLOGY; NONHUMAN; ONCOGENE NEU; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; TUMOR REGRESSION; VACCINATION; VITILIGO;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; VACCINATION;

EID: 0141630355     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0463.2003.11107813.x     Document Type: Review

References (137)

1. de St Groth BE DCs and peripheral T cell tolerance. Semin Immunol 2001;13:311-22.
2. Lanzavecchia A, Sallusto F. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol 2001;13:291-8.
3. Knuth A, Wolfel T, Meyer zum Buschenfelde KH. T cell responses to human malignant tumours. Cancer Surv 1992;13:39-52.
4. Mailliard RB, Dallal RM, Son YI, Lotze MT. Dendritic cells promote T-cell survival or death depending upon their maturation state and presentation of antigen. Immunol Invest 2000;29:177-85.
5. Garrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F. HLA class I antigens in human tumors. Adv Cancer Res 1995;67:155-95.
6. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000;18:245-73.
7. Syme RM, Bryan TL, Gluck S. Dendritic cell-based therapy: a review focusing on antigenic selection. J Hematother Stem Cell Res 2001;10:601-8.
8. Bell D, Young JW, Banchereau J. Dendritic cells. Adv Immunol 1999;72:255-324.
9. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
10. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-87.
11. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
12. Grabbe S, Kampgen E, Schuler G. Dendritic cells: multi-lineal and multi-functional. Immunol Today 2000;21:431-3.
13. Reid SD, Penna G, Adorini L. The control of T cell responses by dendritic cell subsets. Curr Opin Immunol 2000;12:114-21.
14. Takamizawa M, Rivas A, Fagnoni F, Benike C, Kosek J, Hyakawa H, et al. Dendritic cells that process and present nominal antigens to naive T lymphocytes are derived from CD2+ precursors. J Immunol 1997;158:2134-42.
15. Robert C, Fuhlbrigge RC, Kieffer JD, Ayehunie S, Hynes RO, Cheng G, et al. Interaction of dendritic cells with skin endothelium: a new perspective on immunosurveillance. J Exp Med 1999;189:627-36.
16. Greaves DR, Wang W, Dairaghi DJ, Dieu MC, Saint-Vis B, Franz-Bacon K, et al. CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3 alpha and is highly expressed in human dendritic cells. J Exp Med 1997;186:837-44.
17. Penna G, Sozzani S, Adorini L. Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J Immunol 2001;167:1862-6.
18. Engering AJ, Cella M, Fluitsma D, Brockhaus M, Hoefsmit EC, Lanzavecchia A, et al. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur J Immunol 1997;27:2417-25.
19. Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 1998;188:2163-73.
20. Inaba K, Pack M, Inaba M, Sakuta H, Isdell F, Steinman RM. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J Exp Med 1997;186:665-72.
21. Wada H, Ono T, Uenaka A, Monden M, Nakayama E. Requirement of CD4+ T cells and antigen-presenting cells for primary in vitro generation of CD8+ cytotoxic T cells against Ld-binding self-peptide p2Ca. Immunology 1995;84:633-7.
22. Hauss P, Selz F, Cavazzana-Calvo M, Fischer A. Characteristics of antigen-independent and antigen-dependent interaction of dendritic cells with CD4+ T cells. Eur J Immunol 1995;25:2285-94.
23. Damle NK, Klussman K, Aruffo A. Intercellular adhesion molecule-2, a second counter-receptor for CD11a/CD18 (leukocyte function-associated antigen-1), provides a costimulatory signal for T-cell receptor-initiated activation of human T cells. J Immunol 1992;148:665-71.
24. Caux C, Vanbervliet B, Massacrier C, Azuma M, Okumura K, Lanier LL, et al. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells. J Exp Med 1994;180:1841-7.
25. Starling GC, McLellan AD, Egner W, Sorg RV, Fawcett J, Simmons DL, et al. Intercellular adhesion molecule-3 is the predominant co-stimulatory ligand for leukocyte function antigen-1 on human blood dendritic cells. Eur J Immunol 1995;25:2528-32.
26. Czerniecki BJ, Cohen PA, Faries M, Xu S, Roros JG, Bedrosian I. Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines. Crit Rev Immunol 2001;21:157-78.
27. Fearnley DB, Whyte LF, Carnoutsos SA, Cook AH, Hart DN. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood 1999;93:728-36.
28. Cao H, Verge V, Baron C, Martinache C, Leon A, Scholl S, et al. In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy. J Hematother Stem Cell Res 2000;9:183-94.
29. Wong EC, Maher VE, Hines K, Lee J, Carter CS, Goletz T, et al. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy 2001;3:19-29.
30. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001;98:8809-14.
31. Marroquin CE, Westwood JA, Lapointe R, Mixon A, Wunderlich JR, Caron D, et al. Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J Immunother 2002;25:278-88.
32. Morse MA, Vredenburgh JJ, Lyerly HK. A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy. J Hematother Stem Cell Res 1999;8:577-84.
33. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999;223:1-15.
34. De Vries IJ, Eggert AA, Scharenborg NM, Vissers JL, Lesterhuis WJ, Boerman OC, et al. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother 2002;25:429-38.
35. Guyre CA, Fisher JL, Waugh MG, Wallace PK, Tretter CG, Ernstoff MS, et al. Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications. J Immunol Methods 2002;262:85-94.
36. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-8.
37. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213-22.
38. Feuerstein B, Berger TG, Maczek C, Roder C, Schreiner D, Hirsch U, et al. A method for the production of cryopreserved aliquots of antigenpreloaded, mature dendritic cells ready for clinical use. J Immunol Methods 2000;245:15-29.
39. Lewallel P, Rouas R, Lehmann F, Martiat P. Freezing of dendritic cells, generated from cryopreserved leukaphereses, does not influence their ability to induce antigen-specific immune responses or functionally react to maturation stimuli. J Immunol Methods 2000;240:69-78.
40. Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from bench to bedside. Nat Med 2001;7:761-5.
41. Zhou Y, Bosch ML, Salgaller ML. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother 2002;25:289-303.
42. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5:1289-97.
43. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996;56:2479-83.
44. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999;5:1331-8.
45. Okugawa T, Ikuta Y, Takahashi Y, Obata H, Tanida K, Watanabe M, et al. A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals. Eur J Immunol 2000;30:3338-46.
46. Nair SK, Boczkowski D, Morse, M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Int J Cancer 1999;82:121-4.
47. Osman Y, Takahashi M, Zheng Z, Koike T, Toba K, Liu A, et al. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) pepfide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 1999;13:166-74.
48. Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000;95:1781-7.
49. Stuhler G, Zobywalski A, Grunebach F, Brossart P, Reichardt VL, Barth H, et al. Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters. Proc Natl Acad Sci U S A 1999;96:1532-5.
50. Bennett SR, Carbone FR, Karamalis F, Miller JE Heath WR. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 1997;186:65-70.
51. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
52. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998;188:2199-204.
53. Bellone M, Iezzi G, Martin-Fontecha A, Rivolta L, Manfredi AA, Protti MP, et al. Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells. J Immunol 1997;158:783-9.
54. el Shami K, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, et al. MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 1999;29:3295-301.
55. Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon M J, Parham GP. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol 2000;96:422-30.
56. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001;61:842-7.
57. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigenpulsed dendritic cells. Nat Med 1996;2:52-8.
58. Norbury CC, Chambers BJ, Prescott AR, Ljunggren HG, Watts C. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol 1997;27:280-8.
59. Brossart P, Bevan MJ. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 1997;90:1594-9.
60. Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997;158:2723-30.
61. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide or tumor-lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
62. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 1998;95:9482-7.
63. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998;188:1359-68.
64. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423-34.
65. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;6:332-6.
66. Scott-Taylor TH, Pettengell R, Clarke I, Stuhler G, La Barthe MC, Walden P, et al. Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta 2000;1500:265-79.
67. Lee G, Delohery TM, Ronai Z, Brandt-Rauf PW, Pincus MR, Murphy RB, et al. A comparison of techniques for introducing macromolecules into living cells. Cytometry 1993;14:265-70.
68. Nestle FO. Dendritic cell vaccination for cancer therapy. Oncogene 2000;19:6673-9.
69. Shu S, Cohen P. Tumor-dendritic cell fusion technology and immunotherapy strategies. J Immunother 2001;24:99-100.
70. Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 2001;166:2953-60.
71. Mitchell DA, Nair SK. RNA transfected dendritic cells as cancer vaccines. Curr Opin Mol Ther 2000;2:176-81.
72. Mitchell DA, Nair SK. RNA-transfected dendritic cells in cancer immunotherapy. J Clin Invest 2000;106:1065-9.
73. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-72.
74. Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 2001;61:3388-93.
75. Ni HT, Spellman SR, Jean WC, Hall WA, Low WC. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 2001;51:1-9.
76. Kirk CJ, Mule JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 2000;11:797-806.
77. Jenne L, Schuler G, Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 2001;22:102-7.
78. Arthur JF, Butterfield LH, Roth MD, Bui LA, Kiertscher SM, Lau R, et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997;4:17-25.
79. Rughetti A, Biffoni M, Sabbatucci M, Rahimi H, Pellicciotta I, Fattorossi A, et al. Transfected human dendritic cells to induce antitumor immunity. Gene Ther 2000;7:1458-66.
80. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999;59:56-8.
81. Kukutsch NA, Rossner S, Austyn JM, Schuler G, Lutz MB. Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells. J Invest Dermatol 2000;115:449-53.
82. Eggert AAO, Schreurs MWJ, Boerman OC, Oyen WJC, de Boer AJ, Punt CJA, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999;59:3340-5.
83. Barratt-Boyes SM, Watkins SC, Finn OJ. In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. J Immunol 1997;158:4543-7.
84. Barratt-Boyes SM, Zimmer MI, Harshyne LA, Meyer EM, Watkins SC, Capuano S III, et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J Immunol 2000;164:2487-95.
85. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001;166:4254-9.
86. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
87. Serody JS, Edward J, Tisch RM, Kuhns JJ, Frelinger JA. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J Immunol 2000;164:4961-7.
88. Simon RM, Steinberg SM, Hamilton M, Hildesheim A, Khleif S, Kwak LW, et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 2001;19:1848-54.
89. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517-26.
90. Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999;93:2411-9.
91. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000;6:621-7.
92. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigenloaded dendritic cells. J Clin Oncol 2000;18:3894-903.
93. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving; patients with hormone-refractory metastatic disease. Prostate 1999;38:73-8.
94. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001;167:7150-6.
95. Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, et al. Mage3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocytederived dendritic cells. J Immunol 2000;165:3492-6.
96. Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 2000;86:385-92.
97. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-8.
98. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002;195:1279-88.
99. Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, et al. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 1997;32:272-8.
100. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998;36:39-44.
101. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96:3102-8.
102. Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K, et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 2001;7:23-31.
103. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001;7:2277-84.
104. Krause SW, Neumann C, Soruri A, Mayer S, Peters JH, Andreesen R. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 2002;25:421-8.
105. Birmingham K. Misconduct trouble brewing in Gottingen. Nat Med 2001;7:875.
106. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001;61:8513-9.
107. Höltl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999;161:777-82.
108. Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 2001;48:347-51.
109. Saenz-Badillos J, Amin SP, Granstein RD. RNA as a tumor vaccine: a review of the literature. Exp Dermatol 2001;10:143-54.
110. Kirk CJ, Mule JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 2000;11:797-806.
111. Offringa R, van der Burg SH, Ossendorp F, Toes RE, Melief CJ. Design and evaluation of antigen-specific vaccination strategies against cancer. Curr Opin Immunol 2000;12:576-82.
112. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002;25:97-138.
113. Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, et al. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer 2001;92:703-11.
114. Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, et al. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol Immunother 2000;49:517-29.
115. Schmittel A, Keilholz U, Scheibenbogen C. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J Immunol Methods 1997;210:167-74.
116. Maecker HT, Dunn HS, Suni MA, Khatamzas E, Pitcher CJ, Bunde T, et al. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J Immunol Methods 2001;255:2740.
117. Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, Cerottini JC, et al. Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods 2000;244:81-9.
118. Yamshchikov G, Thompson L, Ross WG, Galavotti H, Aquila W, Deacon D, et al. Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations. Clin Cancer Res 2001;7(3 Suppl):909-16s.
119. Maecker HT, Auffermann-Gretzinger S, Nomura LE, Liso A, Czerwinski DK, Levy R. Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry. Clin Cancer Res 2001;7(3 Suppl):902-8s.
120. Karanikas V, Lodding J, Maino VC, McKenzie IF. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. Clin Cancer Res 2000;6:829-37.
121. Scheibenbogen C, Schmittel A, Keilholz U, Allgauer T, Hofmann U, Max R, et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 2000;23:275-81.
122. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anticarcinoembryonic antigen immune responses. J Clin Oncol 2000;18:3964-73.
123. Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999;5:2756-65.
124. Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001;19:3836-47.
125. Monsurro V, Nielsen MB, Perez-Diez A, Dudley ME, Wang E, Rosenberg SA, et al. Kinetics of TCR use in response to repeated epitope-specific immunization. J Immunol 2001;166:5817-25.
126. Ranieri E, Kierstead LS, Zarour H, Kirkwood JM, Lotze MT, Whiteside T, et al. Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest 2000;29:121-5.
127. Kammula US, Marincola FM, Rosenberg SA. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst 2000;92:1336-44.
128. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
129. Foon KA, John WJ, Chakraborty M, Das R, Teitelbaum A, Garrison J, et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 1999;17:2889-5.
130. Hsueh EC, Gupta RK, Qi K, Morton DL. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998;16:2913-20.
131. Takahashi T, Johnson TD, Nishinaka Y, Morton DL, Irie RE IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol 1999;112:205-9.
132. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-44.
133. Alexander J, Fikes J, Hoffman S, Franke E, Sacci J, Appella E, et al. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol Res 1998;18:79-92.
134. Miyahira Y, Murata K, Rodriguez D, Rodriguez JR, Esteban M, Rodrigues MM, et al. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J Immunol Methods 1995;181:45-54.
135. Suni MA, Picker LJ, Maino VC. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods 1998;212:89-98.
136. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 1999;59:2675-81.
137. Schrama D, Andersen MH, Terheyden P, Schroder L, Pedersen LO, thor Straten P, et al. Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients. Cancer Res 2001;61:493-6.